Research Center: Boston Children’s Hospital
Location: 300 Longwood Ave, Boston, MA 02115, United States
Lead Researcher: Wanda Phipatanakul MD, MS
IRB: This study has been reviewed and approved by the BRANY central Institutional Review Board

Do you, your child, or a loved one struggle with atopic dermatitis? This study explores how certain characteristics of the skin relate to the severity of AD and how the skin responds to different treatments. By participating, you can help researchers uncover crucial insights that could lead to better, more effective therapies for AD.

Join this research study to potentially improve the future treatment and care of those living with atopic dermatitis. The information gathered may someday transform how AD is managed, offering new hope and relief for millions. Be a part of this innovative research and make a difference in the fight against atopic dermatitis.

Please note that parental consent is needed for participants under the age of 18 to participate in this study.

• Participants will receive specialized Eczema care and treatment at no cost.
• Eligible participants will be compensated for their time and participation.
• Participants may experience improvements in symptoms associated with atopic dermatitis.
• Participants will be contributing valuable information that may benefit those with AD in the future.
• Participants will be helping to advance medical research.

• If you decide to participate in the study and later feel that you or your child no longer wish to be part of it, you can withdraw at any time.
• Any information that you or your child provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your or your child’s health as it relates to the study.

• People aged 6 years old or older
• Must not have a known hypersensitivity to any of the excipients of the study treatments (Vanicream™, hydrocortisone, triamcinolone, or dupilumab).
• Must be able and willing to apply a stable dose of the study-provided topical moisturizer at least twice daily if no known hypersensitivity.
• Must not have asthma requiring a dose greater than 880 mcg/day of fluticasone propionate or equivalent inhaled corticosteroid to maintain asthma control.
• Must not have been diagnosed with human immunodeficiency virus (HIV) infection.
• Must not have been diagnosed with cancer within the past 5 years, excluding completely treated in situ carcinoma of the cervix, and completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin or melanoma in situ.
• Must not have a history of non-malignant lymphoproliferative disorders.
• Must not have a history of alcohol or drug abuse within the past 2 years.
• Must not have a history of keloid formation if an adult.
• Must not have a history of serious life-threatening hypersensitivity to tape or adhesives.
• Must not have a known hypersensitivity to local anesthetics (e.g., Lidocaine or Novocaine) if an adult.
• Must not have been diagnosed with any bleeding disorder or other conditions requiring treatment with anticoagulants.
• Must not have any planned major surgical procedures.
• Must not have been diagnosed with any parasitic infection within the past 12 months.
• Must not be pregnant, breastfeeding, or planning to become pregnant.
• Must be able to attend up to 10 study visits at the research site over approximately 6-8 months.

The study team will explain the research in its entirety but some details are:

• Participants will be asked to complete up to 10 study visits where clinical staff will ask about health, medical history, and current medications or therapies.
• Participants will be asked to provide blood and skin samples during the study.
• Participants will be asked to refrain from applying topical steroids to a specified target area between the Baseline Assessment and Day 7 Visits.

Boston Children’s Hospital
The research enterprise at Boston Children’s Hospital, involving over 3,000 researchers, is the largest in the world at a pediatric center. Their work is driven by a profound understanding of disease biology and supported by advanced discovery platforms such as genetics and genomics, gene editing, bioinformatics, proteomics, bioengineering, image analysis, biobanks, disease-specific stem cell lines, and various animal models. Boston Children’s research enterprise excels in rare disease discovery, features a robust Translational Research Program, and benefits from large, diverse patient populations for clinical research and trials.
The Division of Immunology at Boston Children’s is renowned for its pioneering research in allergic and immunological mechanisms, particularly IgE regulation. This includes the pathogenesis of Atopic Dermatitis